343 results on '"Glimm H"'
Search Results
2. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib® versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]
3. Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
4. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma
5. Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma
6. Development of expandable patient-derived 3D sarcoma cultures for bone sarcoma research
7. The German Network for Personalized Medicine to enhance patient care and translational research
8. 99P Fibroblast activation protein alpha (FAP) as theranostic target in solitary fibrous tumor
9. Personalisierte Onkologie
10. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment
11. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
12. 487P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
13. 56P Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study
14. 198P Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial
15. 196P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
16. 1784TiP Pasireotide as maintenance treatment in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor: The PAMSARC study
17. Outcome of immuncheckpoint inhibitor therapy in adrenocortical carcinoma - A multicenter retrospective study
18. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling
19. Hematopoietic Ex Vivo Gene Transfer
20. Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway
21. NDRG1 prognosticates the natural course of disease in WHO grade II glioma
22. 1533P Gene expression-based prediction of pazopanib benefit in sarcomas
23. What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
24. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*
25. Gene expression-based prediction of pazopanib benefit in sarcomas
26. Sarcoma classification by DNA methylation profiling
27. 2318P Value of broad molecular profiling for cancer diagnosis
28. 1940P Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
29. 1936P Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
30. 187P Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial
31. 131O A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort
32. Hämatopoetische Stammzelltherapie: Biologische Grundlagen
33. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease
34. Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway.
35. 10-Year stability of clinical-grade serum-free γ-retroviral vector-containing medium
36. Human colon cancer metastases initiating cells express mesenchymal markers and reside in the bone marrow in a mouse xenotransplantation model: V638
37. 10-Year stability of clinical-grade serum-free c-retroviral vector-containing medium
38. Abcb4-knockout reduces hepatic lipid steatosis in HBs transgenic mice
39. YAP-induced tumor initiation mediates a switch in hepatic macrophage identity via the Ccl2/Ccr2 axis
40. Distinct classes of tumor initiating cells form tumor and metastases in human colon cancer: V751
41. Harmonization and standardization of panel-based tumour mutational burden (TMB) measurement: Real-world results and recommendations of the QuIP study
42. Hematopoietic activity of human short term repopulating cells in mobilized peripheral blood cell transplants is restricted to the first 20 weeks after transplantation: V394
43. Electrophysiological properties of neurones in cultures from postnatal rat dentate gyrus
44. Reduced early output of megakaryocytic and erythroid cells from human cord blood compared to mobilized peripheral blood and bone marrow short term repopulating cells assessed in a quantitative NOD/SCID-b2m-/- mouse xenotransplant model: P732
45. Hematopoiesis and Different Stem Cell Sources: 2.5.1
46. Human short term repopulating cells contribute to early hematopoietic reconstitution from cultured peripheral blood stem cell transplants in patients: 524
47. Characterization of Human Hematopoietic Cells with Short-Lived in Vivo Repopulating Activity
48. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin-null mice
49. Randomized Phase 2 Study of Trabectedin/Olaparib Compared to Physician‘s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Haboring DNA Repair Deficiencies (DKTK/NCT-PMO-1603, TOP-ART
50. Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.